The company was founded in 2005 and is headquartered in San Diego, California. aTyr has scheduled an FDA Type C Meeting for mid-April 2026 to review Phase 3 EFZO-FIT study results from pulmonary sarcoidosis. aTyr has a partnership with Kyorin Pharmaceutical with a total deal value up to $175M for development and commercialization of efzofitimod for ILD in Japan.
Cyborg Score Rationale
aTyr demonstrates clinical-stage progress with Phase 3 data readout imminent and multiple rare disease designations. The partnership with Kyorin provides near-term revenue potential. However, the company remains pre-commercial with limited cash runway and dependency on trial outcomes.
Top Insights
Phase 3 EFZO-FIT trial in pulmonary sarcoidosis completed with FDA Type C meeting scheduled for April 2026
Multiple orphan drug designations (US, EU, Japan) and Fast Track status provide regulatory advantages and potential accelerated pathways
Kyorin partnership worth up to $175M de-risks Japan commercialization and provides validation for efzofitimod platform
Early-stage platform approach with 20 tRNA synthetase-derived candidates targets inflammation and fibrosis across multiple indications
Named Competitors
Pirfenidone — Anti-fibrotic approved for IPF; competitive standard of care
Nintedanib — Tyrosine kinase inhibitor approved for multiple ILD indications
Apremilast — Phosphodiesterase-4 inhibitor for systemic sclerosis and ILD
Recent Developments
(Feb 2026) FDA Type C Meeting scheduled for mid-April 2026 to discuss EFZO-FIT Phase 3 results in pulmonary sarcoidosis
(Feb 2026) Inducement grants announced under Nasdaq Listing Rule 5635(c)(4)
(Ongoing 2026) Phase 2 EFZO-CONNECT study continuing in patients with SSc-ILD
Open the full interactive aTyr Pharma report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.